Advinus sets up US operations
This article was originally published in Scrip
Advinus Therapeutics, an Indian contract research services and discovery company, has commenced operations in the US. It has set up a wholly owned subsidiary, Advinus Therapeutics , with an office in Research Triangle Park, North Carolina. Advinus expects the US operations to help the company build on its client base and collaborations and also expand into new ones. Advinus already has a string of R&D alliances with Merck & Co, Ortho-McNeil-Janssen Pharmaceuticals and the Drugs for Neglected Diseases initiative, Geneva, among others. Advinus, which is part of India's diversified Tata group, has also appointed Dr Eric Nelson as global head of business development, marketing and strategy. Dr Nelson, who will be based out of the company's US office and will manage its operations there, joins Advinus from Tranzyme Pharma where he was vice president of business development and licensing.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.